Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Clinical evidence

ACTRN12621000011886

46 evidence topics · 3 sources

Objective
Location and study date
Registration, enrollment, and data collection dates in the ANZCTR record
FieldQuoted record
Date submitted“26/11/2020”
Date registered“11/01/2021”
Type of registration“Prospectively registered”
Recruitment status“Completed”
Date of first participant enrolment, anticipated“29/01/2021”
Date of first participant enrolment, actual“17/02/2021”
Date of last participant enrolment, anticipated“17/11/2021”
Date of last participant enrolment, actual“19/01/2022”
Date of last data collection, anticipated“30/11/2021”
Date of last data collection, actual“4/02/2022”
Date last updated“14/06/2022”
Recruitment state and principal investigator site in Adelaide, Australia, in the ANZCTR record
Results documents and data sharing in the ANZCTR record
FieldQuoted record
Will the study consider sharing individual participant data?“No”
Study design
Study type, allocation, control, and phase in the ANZCTR record
FieldQuoted record
Health condition(s) studied“Psoriasis”
Study type“Interventional”
Purpose of the study“Treatment”
Allocation to intervention“Randomised controlled trial”
Control group“Placebo”
Phase“Phase 1”
Secondary sponsor, funding, and ethics approval in the ANZCTR record
FieldQuoted record
Funding source category“Commercial sector/Industry”
Secondary sponsor name“Avance Clinical Pty Ltd”
Ethics committee name“Bellberry Human Research Ethics Committee”
Ethics approval date“10/12/2020”
Ethics approval number“2020-11-1116”
Eligibility criteria
Key exclusion criteria in the ANZCTR record
CriterionQuoted record
Significant disease“History or presence of significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease, including any acute illness or major surgery within the past 3 months determined by the PI to be clinically relevant.”
Current infection“Current infection that requires systemically absorbed antibiotic, antifungal, antiparasitic or antiviral medications.”
Malignancy“Any history of malignant disease in the last 10 years (excludes surgically resected skin squamous cell or basal cell carcinoma).”
Immunosuppression“Presence of clinically relevant immunosuppression from, but not limited to, immunodeficiency conditions such as common variable hypogammaglobulinemia.”
Immunosuppressive or immunomodulating medications“Use of or plans to use systemic immunosuppressive (e.g., corticosteroids, methotrexate, azathioprine, cyclosporine) or immunomodulating medications (e.g., interferon) during the study or within 3 months prior to the first study drug administration.”
Skin findings“Presence or evidence of recent sunburn, scar tissue, tattoo (more than 25% of body area), open sore, or branding that, in the opinion of the Investigator, would interfere with interpretation of skin adverse reaction assessments.”
Liver function tests“Liver function test results elevated more than 1.5-fold above the upper limit of normal (ULN) for gamma glutamyl transferase [GGT], bilirubin (total, conjugated and unconjugated) or alkaline phosphatase (ALP) or elevated 2.0-fold above ULN for aspartate aminotransferase (AST) or alanine aminotransferase (ALT).”
Viral infection“Positive test results for active human immunodeficiency virus (HIV-1 and HIV-2), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies at the screening visit.”
Tuberculosis“History of active, latent or inadequately treated tuberculosis infection.”
Conditions affecting drug disposition“Presence or having sequelae of gastrointestinal, liver (including Gilbert’s syndrome), kidney, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.”
Renal function“Estimated creatinine clearance (CrCl) < 60 mL/min using the Cockcroft-Gault formula or serum creatinine more than 1.5-fold above the ULN.”
Concomitant medication“Use of any systemically absorbed prescription or over-the-counter medication (including herbal products, diet aids, and hormone supplements) within 10 days or 5 half-lives of the medication (whichever is longer) prior to the first study drug administration, except occasional use of paracetamol (up to a maximum of 4 doses per day of 500-mg paracetamol, and no more than 3g per week).”
Interferon hypersensitivity“Known hypersensitivity to interferon alfa or any component of the product (Part B only).”
Vaccination“Use of any vaccinations within 30 days prior to the first study drug administration.”
Other investigational trials“Participation in another investigational clinical trial within 60 days (or 5 half-lives, of the investigational agent) (whichever is longer) prior to the first study drug administration.”
Treatment
Study outcomes
Rationale for using safety and tolerability as the primary endpoint
Primary and secondary outcomes in the ANZCTR record
Statistical analysis description
Number of participants (Planned and analyzed)
Target and final sample size in the ANZCTR record
FieldQuoted record
Sample size, target“96”
Sample size, final“87”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Plasma pharmacokinetic parameters by single ascending dose and food effect cohort
Parameter5 mg fasted10 mg fasted17.5 mg fasted25 mg fasted50 mg fasted100 mg fastedFood effect cohort, 25 mg fastedFood effect cohort, 25 mg fed
Participants“5 mg Fasted (N = 6)”View highlighted excerpt for this quote“10 mg Fasted (N = 6)”View highlighted excerpt for this quote“17.5 mg Fasted (N = 4)”View highlighted excerpt for this quote“25 mg Fasted (N = 5)”View highlighted excerpt for this quote“50 mg Fasted (N = 5)”View highlighted excerpt for this quote“100 mg Fasted (N = 5)”View highlighted excerpt for this quote“FE cohort 25 mg Fasted (N = 6)”View highlighted excerpt for this quote“FE cohort 25 mg Fed (N = 6)”View highlighted excerpt for this quote
Cmax, ng/mL“38.6 (22)”View highlighted excerpt for this quote“93.0 (28)”View highlighted excerpt for this quote“217 (19)”View highlighted excerpt for this quote“253 (21)”View highlighted excerpt for this quote“603 (24)”View highlighted excerpt for this quote“949 (15)”View highlighted excerpt for this quote“272 (13)”View highlighted excerpt for this quote“131 (22)”View highlighted excerpt for this quote
Tmax, h“0.75 (0.75–2.00)”View highlighted excerpt for this quote“0.88 (0.75–4.00)”View highlighted excerpt for this quote“1.13 (0.75–2.00)”View highlighted excerpt for this quote“1.00 (1.00–1.50)”View highlighted excerpt for this quote“1.00 (0.50–1.50)”View highlighted excerpt for this quote“1.00 (0.75–6.00)”View highlighted excerpt for this quote“0.75 (0.50–1.00)”View highlighted excerpt for this quote“4.00 (4.00–6.00)”View highlighted excerpt for this quote
AUC0–t, h*ng/mL“326 (29)”View highlighted excerpt for this quote“794 (24)”View highlighted excerpt for this quote“1896 (5)”View highlighted excerpt for this quote“2110 (18)”View highlighted excerpt for this quote“4097 (24)”View highlighted excerpt for this quote“11,092 (14)”View highlighted excerpt for this quote“1829 (13)”View highlighted excerpt for this quote“1802 (20)”View highlighted excerpt for this quote
AUC0–inf, h*ng/mL“336 (28)”View highlighted excerpt for this quote“816 (26)”View highlighted excerpt for this quote“1925 (5)”View highlighted excerpt for this quote“2138 (18)”View highlighted excerpt for this quote“4137 (24)”View highlighted excerpt for this quote“11,286 (14)”View highlighted excerpt for this quote“1850 (14)”View highlighted excerpt for this quote“1833 (20)”View highlighted excerpt for this quote
AUC0–24h, h*ng/mL“283 (26)”View highlighted excerpt for this quote“675 (18)”View highlighted excerpt for this quote“1662 (4)”View highlighted excerpt for this quote“1873 (20)”View highlighted excerpt for this quote“3678 (21)”View highlighted excerpt for this quote“9379 (14)”View highlighted excerpt for this quote“1642 (13)”View highlighted excerpt for this quote“1550 (20)”View highlighted excerpt for this quote
t½, h“8.66 (22)”View highlighted excerpt for this quote“9.26 (18)”View highlighted excerpt for this quote“7.85 (19)”View highlighted excerpt for this quote“7.97 (11)”View highlighted excerpt for this quote“7.48 (10)”View highlighted excerpt for this quote“8.11 (13)”View highlighted excerpt for this quote“7.60 (17)”View highlighted excerpt for this quote“7.91 (14)”View highlighted excerpt for this quote
CL/F, L/h“14.9 (36)”View highlighted excerpt for this quote“12.3 (21)”View highlighted excerpt for this quote“9.1 (5)”View highlighted excerpt for this quote“11.7 (17)”View highlighted excerpt for this quote“12.1 (23)”View highlighted excerpt for this quote“8.9 (13)”View highlighted excerpt for this quote“13.5 (13)”View highlighted excerpt for this quote“13.6 (21)”View highlighted excerpt for this quote
Vz/F, L“186 (20)”View highlighted excerpt for this quote“164 (13)”View highlighted excerpt for this quote“103 (18)”View highlighted excerpt for this quote“134 (27)”View highlighted excerpt for this quote“130 (14)”View highlighted excerpt for this quote“104 (20)”View highlighted excerpt for this quote“148 (19)”View highlighted excerpt for this quote“156 (28)”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-emergent adverse events by single ascending dose cohort
Event5 mg fasted (N = 6)10 mg fasted (N = 6)17.5 mg fasted (N = 4)25 mg fasted (N = 6)50 mg fasted (N = 6)100 mg fasted (N = 5)Food effect cohort, 25 mg fasted (N = 7)Food effect cohort, 25 mg fed (N = 7)Total active (N = 41)Pooled placebo (N = 12)
Participant with at least 1 TEAE“3 (50.0) [7]”View highlighted excerpt for this quote“3 (50.0) [4]”View highlighted excerpt for this quote“3 (75.0) [8]”View highlighted excerpt for this quote“4 (66.6) [8]”View highlighted excerpt for this quote“6 (100.0) [18]”View highlighted excerpt for this quote“5 (100.0) [22]”View highlighted excerpt for this quote“4 (57.1) [14]”View highlighted excerpt for this quote“4 (57.1) [15]”View highlighted excerpt for this quote“32 (78.0) [96]”View highlighted excerpt for this quote“5 (41.6) [9]”View highlighted excerpt for this quote
Mild“3 (50.0) [6]”View highlighted excerpt for this quote“3 (50.0) [4]”View highlighted excerpt for this quote“3 (75.0) [8]”View highlighted excerpt for this quote“4 (66.6) [8]”View highlighted excerpt for this quote“6 (100.0) [18]”View highlighted excerpt for this quote“5 (100.0) [20]”View highlighted excerpt for this quote“4 (57.1) [13]”View highlighted excerpt for this quote“4 (57.1) [13]”View highlighted excerpt for this quote“32 (78.0) [90]”View highlighted excerpt for this quote“5 (41.6) [9]”View highlighted excerpt for this quote
Moderate“1 (16.6) [1]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (40.0) [2]”View highlighted excerpt for this quote“1 (14.2) [1]”View highlighted excerpt for this quote“2 (28.5) [2]”View highlighted excerpt for this quote“6 (14.6) [6]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Severe“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TEAEs considered related to the study drug“1 (16.6) [2]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (75.0) [5]”View highlighted excerpt for this quote“4 (66.6) [6]”View highlighted excerpt for this quote“4 (66.6) [8]”View highlighted excerpt for this quote“5 (100.0) [20]”View highlighted excerpt for this quote“4 (57.1) [5]”View highlighted excerpt for this quote“4 (57.1) [9]”View highlighted excerpt for this quote“25 (60.9) [55]”View highlighted excerpt for this quote“2 (16.6) [3]”View highlighted excerpt for this quote
TEAEs leading to study drug discontinuation“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (14.2) [1]”View highlighted excerpt for this quote“1 (2.4) [1]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Any serious TEAE“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Headache“0”View highlighted excerpt for this quote“2 (33.3) [2]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (33.3) [3]”View highlighted excerpt for this quote“5 (83.3) [5]”View highlighted excerpt for this quote“5 (100.0) [5]”View highlighted excerpt for this quote“3 (42.8) [3]”View highlighted excerpt for this quote“3 (42.8) [6]”View highlighted excerpt for this quote“20 (48.7) [24]”View highlighted excerpt for this quote“3 (25.0) [3]”View highlighted excerpt for this quote
Dizziness“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (25.0) [1]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (20.0) [1]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (28.5) [2]”View highlighted excerpt for this quote“4 (9.7) [4]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Fatigue“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (75.0) [4]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (20.0) [1]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“4 (9.7) [5]”View highlighted excerpt for this quote“1 (8.3) [1]”View highlighted excerpt for this quote
Nausea“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (16.6) [1]”View highlighted excerpt for this quote“2 (33.3) [2]”View highlighted excerpt for this quote“5 (100) [5]”View highlighted excerpt for this quote“1 (14.2) [1]”View highlighted excerpt for this quote“1 (14.2) [1]”View highlighted excerpt for this quote“10 (24.3) [10]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Catheter site bruise“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (16.6) [2]”View highlighted excerpt for this quote
Incidence, severity, relatedness, and discontinuations in the single ascending dose part

“In the SAD part, 37 (69.8%) participants experienced 105 TEAEs; 32 (78.0%) participants receiving ESK‐001 experienced 96 TEAEs and 5 (41.6%) participants receiving placebo experienced 9 TEAEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Most TEAEs (94.3%) were mild in severity and a few moderate in severity (all following administration of ESK‐001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“There were no dose‐related trends in the incidence and severity of TEAEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Two participants in the FE cohort discontinued the study drug and study due to TEAEs indicative of a possible COVID‐19 infection, one after 1 dose (fed) in Period 1 due to upper respiratory tract infection, and one after 1 dose (fasted) in Period 1 due to sinus congestion, cough, and sneezing, all mild in severity and not related to study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The most common TEAE (reported in ≥30% of the participants in any group) by preferred term was a headache.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the cohorts receiving ESK‐001, most TEAEs were considered related to the study drug by the investigator; 25 (61.0%) participants receiving ESK‐001 experienced 55 TEAEs considered related to the study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Two (16.6%) participants receiving placebo experienced 3 TEAEs considered related to placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“There were no apparent treatment or dose‐related trends in the clinical laboratory results and no TEAEs arising from abnormalities in clinical laboratory results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Study limitations
Summary
  • The authors note that the study provided short-term exposure data, so chronic effects such as cumulative toxicity were not captured.
  • The multiple ascending dose part is reported in supplementary figures and tables, and its biomarker results and the concentration-QTc results are reported as data not shown.
  • Participants were healthy adults dosed with a liquid formulation of ESK-001.
  • Because of the COVID-19 pandemic, the 17.5 mg and 100 mg cohorts could not be filled to the planned 8 participants (N = 4 and N = 5 in the pharmacokinetic table), and 2 food effect cohort participants withdrew with TEAEs indicative of a possible COVID-19 infection.
  • The article and the registry differ: the article reports 91 participants enrolled and a study conducted between January 21, 2021 and February 24, 2022; the ANZCTR record gives a final sample size of 87, a first enrolment on 17/02/2021, and a last data collection on 4/02/2022.
  • No formal sample size calculation was performed. Feces were collected but not analyzed, and urine was collected only for the 50 mg cohort of the single ascending dose part.
  • The ANZCTR record states that no documents have been uploaded by study researchers and answers No to whether the study will consider sharing individual participant data.